About Enoyl-CoA delta isomerase 2
Enoyl-CoA delta isomerase 2 (ECI2) is a protein
from Homo sapiens identified by UniProt accession
O75521, 394 residues long.
MolForge cross-references it against 0 known binders and
72 disease associations.
Target properties
| Protein name | Enoyl-CoA delta isomerase 2 |
| UniProt accession | O75521 |
| Gene | ECI2 |
| Organism | Homo sapiens |
| Length | 394 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (72)
Diseases linked to this target (Open Targets).
- blood metabolite measurement · score 0.29
- generalized anxiety disorder · score 0.25
- balding measurement · score 0.20
- gut microbiome measurement · score 0.18
- depressive symptom measurement · score 0.16
- neuroticism measurement · score 0.07
- isolated asymptomatic elevation of creatine phosphokinase · score 0.07
- attention deficit hyperactivity disorder · score 0.05
- substance abuse · score 0.05
- antisocial behaviour measurement · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75521-F1 | alphafold | PREDICTED | 87.41 | — |
Amino-acid sequence (394 residues)
MAMAYLAWRL ARRSCPSSLQ VTSFPVVQLH MNRTAMRASQ KDFENSMNQV KLLKKDPGNE VKLKLYALYK QATEGPCNMP KPGVFDLINK AKWDAWNALG SLPKEAARQN YVDLVSSLSP SLESSSQVEP GTDRKSTGFE TLVVTSEDGI TKIMFNRPKK KNAINTEMYH EIMRALKAAS KDDSIITVLT GNGDYYSSGN DLTNFTDIPP GGVEEKAKNN AVLLREFVGC FIDFPKPLIA VVNGPAVGIS VTLLGLFDAV YASDRATFHT PFSHLGQSPE GCSSYTFPKI MSPAKATEML IFGKKLTAGE ACAQGLVTEV FPDSTFQKEV WTRLKAFAKL PPNALRISKE VIRKREREKL HAVNAEECNV LQGRWLSDEC TNAVVNFLSR KSKL
Explore Enoyl-CoA delta isomerase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets